Comparative Pharmacology
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDROPANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDROPANE.
BENZTHIAZIDE vs HYDROPANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium reabsorption and increasing excretion of water, sodium, chloride, potassium, and hydrogen ions. Also causes vasodilation via direct arteriolar relaxation.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Adults: 25-50 mg orally once daily initially, may increase to 100 mg daily in a single dose or two divided doses. Maximum dose: 100 mg/day.
50–100 mg orally once daily, maximum 200 mg daily
None Documented
None Documented
Terminal elimination half-life: 8-12 hours; clinical context: supports once-daily dosing for hypertension, but duration of action may extend beyond half-life due to tissue distribution.
Clinical Note
moderateBenzthiazide + Mecamylamine
"The risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Benzthiazide
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzthiazide."
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: ~90% (60% unchanged, 30% as glucuronide conjugate); biliary/fecal: minimal (<5%).
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic